(last updated: Jan 18, 2019)
Thursday, January 24, 2019
08:45 Welcome
Armin Braun, Fraunhofer ITEM
New technologies in lung research
Chair: Katherina Sewald, Fraunhofer ITEM
09:00 Integrating human tissue into research and development
Katherina Sewald, Fraunhofer ITEM
09:30 Ventilator-assisted aerosolized drug delivery: implications for animal models of lung disease
Otmar Schmid, Helmholtz Zentrum München, Germany
10:00 Lung pathophysiology in three dimensions: microfluidic human “small airway-on-a-chip” for clinical translation
Kambez Benam, Colorado, USA
10:30 Coffee break
11:00 A 3D human airway model enables prediction of respiratory toxicity of inhaled drugs in vitro
Kinga Balogh Sivars, AstraZeneca, Sweden
Models of lung infection and asthma exacerbation
Chair: Norbert Krug/Armin Braun, Fraunhofer ITEM
11:30 Asthma remission: The new therapeutic frontier
Antoon van Oosterhout, GSK, United Kingdom
12:00 Genetic determinants of severe respiratory syncytial virus infections in infants
Thomas Pietschmann, TWINCORE, Germany
12:30 Lunch
13:30 Ex vivo human airway epithelium: an innovative model in human parainfluenza virus drug discovery
Patrice Guillon, Gold Coast, Australia
14:00 Testing of novel anti-viral drug candidates in a human ex-vivo lung tissue infection model
Olga Danov, Fraunhofer ITEM
14:30 Microbial airways metagenomics in health and disease
Burkhard Tümmler, Hannover, Germany
15:00 Coffee break
Imaging in respiratory clinical trials
Chair: Jens Hohlfeld, Fraunhofer ITEM
15:30 Imaging endpoints in asthma/COPD clinical trials – an industry perspective
Lars Nordenmark, AstraZeneca, Sweden
16:00 Imaging in IPF clinical trials – an industry perspective
Frank Risse, Boehringer Ingelheim, Germany
16:30 Imaging in respiratory clinical trials – an academic perspective
Jens Vogel-Claussen, Hannover, Germany
17:00 Wine & cheese poster session
and Imaging Round Table
18:30 Awarding of poster prizes
18:45 Guided tours to Fraunhofer ITEM departments:
- PCLS
- Lung function + IPL
- Pathology
- In-vitro testing
- CRC Hannover
19:15 Dinner at the CRC Hannover
21:30 Wrap-up day 1
Friday, January 25, 2019
08:30 Guided tours to Fraunhofer ITEM departments:
- PCLS
- Lung function + IPL
- Pathology
- In-vitro testing
- CRC Hannover
Models of COPD
Chair: Armin Braun, Fraunhofer ITEM
09:00 Utility of animal models in R&D: an evidence-based approach
Marc Kästle, Boehringer Ingelheim, Germany
09:30 Microbial influences in respiratory diseases; the good, the bad and the ugly
Edith Hessel, GSK, United Kingdom
Models of fibrosis
Chair: Antje Prasse, Fraunhofer ITEM
10:00 Development of PLN-74809, an oral dual inhibitor of integrins αVβ6 and αVβ1, for the treatment of idiopathic pulmonary fibrosis
Eric Lefebvre, Pliant Therapeutics, USA
10:30 Coffee break
11:00 In-vitro and in-vivo models to test epithelial-fibroblast interaction
Antje Prasse, Fraunhofer ITEM
11:30 Novel high–throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors
Patrick Sieber, Idorsia, Switzerland
12:00 Molecular diagnostics in interstitial lung diseases
Danny Jonigk, Hannover, Germany
12:30 Molecular motifs of fibrosing pulmonary injury patterns
Mark Kühnel, Hannover, Germany
13:00 Lunch
14:00 Role of integrin signaling in IPF: how to select the right integrin target
Scott Turner, Pliant Therapeutix, USA
14:30 The age effect – a comparative analysis of young and old mice in the bleomycin-induced lung fibrosis model
Stephan Klee, Boehringer Ingelheim, Germany
15:00 What micro CT tells us of IPF?
Wim Wuyts, Leuven, Belgium
15:30 Future therapy landscapes in IPF: building a platform of evidence for strategic positioning
Darcey Black, TherapeutAix UG, Germany
16:00 End of workshop
Fraunhofer Institute for Toxicology and Experimental Medicine